TherapeuticsMD Inc (TXMD)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $21.64M
Last updated: Nov 17, 2026 at 11:00 AM ET
TherapeuticsMD Inc (TXMD) Earnings: Report Dates and Results
TherapeuticsMD (TXMD) is expected to report earnings on Mar 29, 2027. In the quarter ended Sep 30, 2026, TherapeuticsMD reported EPS of $0.04. It beat the EPS estimate in 1 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Next Report
TXMD has an expected report date of Mar 29, 2027.
Earnings History
Of the 33 quarters below that had an estimate, TXMD beat 12, missed 19 and matched 2. The widest gap in the table came in the quarter ended Dec 31, 2022, when EPS landed 841.44% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.04 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 13, 2026 | $1.26M |
| Jun 30, 2026 | $0.01 | N/A | N/A | N/A | N/A | -80.0% | N/A | N/A | Aug 11, 2026 | $869000 |
| Mar 31, 2026 | Not reported | N/A | N/A | N/A | Not reported | N/A | N/A | N/A | May 12, 2026 | $724000 |
| Dec 31, 2025 | Not reported | N/A | N/A | N/A | Not reported | N/A | N/A | N/A | Mar 30, 2026 | $893000 |
| Sep 30, 2025 | Not reported | N/A | N/A | N/A | Not reported | N/A | N/A | N/A | Nov 12, 2025 | $784000 |
| Jun 30, 2025 | $0.05 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 12, 2025 | $952000 |
| Mar 31, 2025 | $0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 13, 2025 | $393000 |
| Dec 31, 2024 | $0.02 | $0.04 | N/A | -45.25% | Miss | N/A | N/A | N/A | Mar 27, 2025 | $667000 |
| Sep 30, 2024 | -$0.05 | $0.04 | N/A | -232.00% | Miss | N/A | N/A | N/A | Nov 12, 2024 | $547000 |
| Jun 30, 2024 | -$0.09 | $0.03 | N/A | -415.00% | Miss | N/A | N/A | N/A | Aug 12, 2024 | $234000 |
| Mar 31, 2024 | -$0.08 | $0.03 | N/A | -355.33% | Miss | N/A | N/A | N/A | May 10, 2024 | $313000 |
| Dec 31, 2023 | -$0.08 | -$0.13 | N/A | +38.46% | Beat | -101.0% | N/A | N/A | Mar 29, 2024 | $502000 |
| Sep 30, 2023 | -$0.32 | -$0.05 | N/A | -540.00% | Miss | N/A | N/A | 0 up, 1 down | Nov 14, 2023 | N/A |
| Jun 30, 2023 | -$0.24 | -$0.07 | -$0.07 - -$0.07 | -242.86% | Miss | -101.9% | 1 | 0 up, 0 down | Aug 14, 2023 | $437000 |
| Mar 31, 2023 | -$0.24 | $0.06 | $0.06 - $0.06 | -500.00% | Miss | N/A | 1 | 0 up, 0 down | May 15, 2023 | $416000 |
| Dec 31, 2022 | $8.23 | -$1.11 | -$1.11 - -$1.11 | +841.44% | Beat | N/A | 1 | 0 up, 0 down | Mar 27, 2023 | $68.57M |
| Sep 30, 2022 | -$3.13 | -$2.04 | N/A | -53.43% | Miss | N/A | 1 | 0 up, 0 down | Nov 14, 2022 | $354000 |
| Jun 30, 2022 | $12.39 | -$3.04 | -$3.04 - -$3.04 | +507.57% | Beat | N/A | 1 | 0 up, 0 down | Aug 15, 2022 | $348000 |
| Mar 31, 2022 | -$5.69 | -$4.00 | -$4.50 - -$3.50 | -42.25% | Miss | N/A | 2 | 0 up, 0 down | May 16, 2022 | $695000 |
| Dec 31, 2021 | -$5.00 | -$3.83 | -$4.50 - -$3.00 | -30.55% | Miss | N/A | 3 | 1 up, 0 down | Mar 10, 2022 | N/A |
| Sep 30, 2021 | -$5.50 | -$5.00 | -$5.00 - -$5.00 | -10.00% | Miss | N/A | 4 | N/A | Nov 11, 2021 | $25.41M |
| Jun 30, 2021 | -$5.50 | -$5.50 | -$6.00 - -$5.00 | 0.00% | In line | N/A | 4 | N/A | Aug 4, 2021 | $23.00M |
| Mar 31, 2021 | -$5.50 | -$5.80 | -$7.50 - -$4.50 | +5.17% | Beat | N/A | 5 | N/A | May 6, 2021 | $19.87M |
| Dec 31, 2020 | -$7.50 | -$5.25 | -$5.50 - -$5.00 | -42.86% | Miss | N/A | 6 | N/A | Mar 2, 2021 | $41.92M |
| Sep 30, 2020 | -$6.00 | -$6.70 | -$7.00 - -$6.50 | +10.45% | Beat | N/A | 6 | N/A | Nov 9, 2020 | N/A |
| Jun 30, 2020 | -$9.50 | -$8.17 | -$9.50 - -$7.50 | -16.28% | Miss | N/A | 7 | N/A | Aug 6, 2020 | $10.70M |
| Mar 31, 2020 | -$10.50 | -$9.30 | -$10.00 - -$8.50 | -12.90% | Miss | N/A | 8 | N/A | May 6, 2020 | $12.25M |
| Dec 31, 2019 | -$9.50 | -$9.36 | -$12.00 - -$8.50 | -1.50% | Miss | N/A | 9 | N/A | Feb 20, 2020 | $15.90M |
| Sep 30, 2019 | -$6.50 | -$9.50 | -$10.00 - -$9.00 | +31.58% | Beat | N/A | 6 | N/A | Nov 6, 2019 | $23.72M |
| Jun 30, 2019 | -$9.50 | -$8.81 | -$10.50 - -$7.00 | -7.83% | Miss | N/A | 7 | N/A | Aug 6, 2019 | $6.08M |
| Mar 31, 2019 | -$8.00 | -$8.49 | -$9.00 - -$7.50 | +5.77% | Beat | N/A | 6 | N/A | May 6, 2019 | $3.95M |
| Dec 31, 2018 | -$8.50 | -$8.50 | -$9.50 - -$6.50 | 0.00% | In line | N/A | 7 | N/A | Feb 21, 2019 | $5.09M |
| Sep 30, 2018 | -$8.00 | -$9.58 | -$15.50 - -$7.50 | +16.49% | Beat | N/A | 6 | N/A | Nov 7, 2018 | $3.47M |
| Jun 30, 2018 | -$7.50 | -$6.17 | -$8.00 - -$4.50 | -21.56% | Miss | N/A | 7 | N/A | Jul 30, 2018 | $3.76M |
| Mar 31, 2018 | -$5.50 | -$4.95 | -$5.50 - -$4.00 | -11.11% | Miss | N/A | 7 | N/A | May 3, 2018 | $3.77M |
| Dec 31, 2017 | -$5.00 | -$4.25 | -$5.50 - -$3.50 | -17.65% | Miss | N/A | 8 | N/A | Feb 20, 2018 | $4.12M |
| Sep 30, 2017 | -$3.50 | -$5.39 | -$8.00 - -$4.00 | +35.06% | Beat | N/A | 8 | N/A | Nov 6, 2017 | $4.42M |
| Jun 30, 2017 | -$5.00 | -$5.43 | -$7.50 - -$4.00 | +7.92% | Beat | N/A | 7 | N/A | Aug 3, 2017 | $4.25M |
| Mar 31, 2017 | -$5.50 | -$5.58 | N/A | +1.43% | Beat | N/A | N/A | N/A | May 2, 2017 | $3.99M |
| Dec 31, 2016 | -$6.00 | -$6.21 | N/A | +3.38% | Beat | N/A | N/A | N/A | Feb 23, 2017 | $4.49M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.07, a profit after a loss of $0.20 per share the year before. It was -$23.50 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.07 | N/A |
| Dec 31, 2024 | -$0.20 | N/A |
| Dec 31, 2023 | -$0.88 | -107.5% |
| Dec 31, 2022 | $11.80 | N/A |
| Dec 31, 2021 | -$21.50 | N/A |
| Dec 31, 2020 | -$33.50 | N/A |
| Dec 31, 2019 | -$33.50 | N/A |
| Dec 31, 2018 | -$29.50 | N/A |
| Dec 31, 2017 | -$19.00 | N/A |
| Dec 31, 2016 | -$23.50 | N/A |
Frequently Asked Questions About TXMD
When is TherapeuticsMD's next earnings date?
TherapeuticsMD's next earnings report is expected for Mar 29, 2027.
How often does TXMD beat earnings estimates?
TherapeuticsMD beat the EPS estimate in 1 of the 8 most recent quarters that had an estimate, with an average surprise of -286.50%.
TXMD pages: Overview, Earnings, Financials, Valuation, Competitors